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ABSTRACT
In the present study, we investigated whether the negative feed-
back action of glucocorticoids (GCs) on the hypothalamo-pituitary-
adrenal (HPA) axis changes with age. We performed a 1-mg dexa-
methasone (DEX) suppression test in 216 healthy elderly individuals.
To investigate individual variability of feedback sensitivity in more
detail, 2.5 yr later a 0.25-mg DEX suppression test was carried out in
164 of the same individuals. We investigated whether there was an
effect of age or gender on both basal and post-DEX cortisol levels, as
well as on the concentration of DEX. Furthermore, we examined
whether the reactions to the two doses of DEX differed, and whether
indications for an intraperson stability of baseline cortisol levels could
be found.
Neither the pre- nor the post-1-mg DEX plasma cortisol concen-
trations showed a correlation with age, and there were no differences
between men and women. The same was true for the pre- and post-
0.25-mg DEX cortisol concentrations. In reaction to 1 mg DEX, over
90% of the subjects investigated showed a cortisol suppression to
levels below 50 nmol/L. After the administration of 0.25 mg DEX,
there was a much wider range in post-DEX cortisol concentrations.
After the administration of 1 mg DEX, there was a significant cor-
relation between liver function parameters and plasma DEX concen-
trations in males, and there was a correlation between body mass
index and plasma DEX concentration in females. Plasma DEX con-
centrations after the administration of 1 mg and 0.25 mg DEX were
closely correlated within subjects (P , 0.001).
There was an intraindividual stability of serum cortisol levels
determined at an interval of 2.5 yr. Furthermore, the individuals with
the highest baseline cortisol concentrations also had the highest post–
0.25-mg DEX cortisol concentrations, indicating a close relationship
between basal cortisol levels and the feedback sensitivity of the HPA
axis to a low dose of DEX. These observations suggest a genetic
influence on the set point of the HPA axis. Aging does not seem to lead
to a change in HPA activity as measured by early morning total
cortisol levels. Also, no changes in the sensitivity of the feedback
system to DEX were observed with age. DEX metabolism is influenced
by liver function (in males) and by body mass index (in females).
(J Clin Endocrinol Metab 83: 47–54, 1998)
GLUCOCORTICOIDS (GCs) are necessary for the nor-mal functioning of most tissues. Even small changes
in the concentrations of circulating GCs may result in a wide
spectrum of physiological and biochemical changes through-
out the body. Under basal conditions, the concentration of
plasma cortisol and the secretion of pituitary ACTH consti-
tute a negative feedback system. Because of the diurnal
rhythm in the rate of ACTH secretion, plasma cortisol levels
are higher in the morning than at night. Both negative feed-
back and diurnal rhythm may be overcome by stress, which
causes increases in ACTH output resulting in plasma cortisol
levels considerably above those found in basal conditions.
Basal concentrations of plasma cortisol exhibit a wide vari-
ation between normal subjects (1). Little is known concerning
the question of whether cortisol levels are stable within sub-
jects. Interperson variation and intraperson stability of
plasma cortisol levels have not been extensively investigated.
For the intraperson constancy, as reported in twins, genetic
factors may be of importance (2, 3). The variation in hypo-
thalamo-pituitary-adrenal (HPA) activity between individ-
uals is thought to be a function of many influences, including
the individual’s feedback sensitivity, circadian rhythm, and
episodic secretion, whereas cortisol binding globulin (CBG)
levels also affect cortisol concentrations (3). Over the years,
the effects of age and gender on the function of the pituitary-
adrenocortical axis have been extensively investigated.
These studies, however, have resulted in contradictory re-
sults. Both circadian patterns of cortisol and ACTH secretion
and random morning plasma cortisol concentrations were
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reported to be unaltered in the elderly (4–7). On the other
hand, an age-related trend towards increased levels of
evening plasma cortisol was reported (8), and increased
mean cortisol levels derived from 24-h frequent sampling
were found in elderly men but not in women (9). Finally,
Waltman et al. (10) reported that aging in humans is not
accompanied by a significant increase in spontaneous ACTH
or cortisol secretion or by a decrease in HPA sensitivity to GC
feedback suppression.
Another controversy in the literature concerns the influ-
ence of age and gender on the dexamethasone (DEX) sup-
pression test (DST). The 1-mg overnight DST is a convenient
screening procedure for patients with Cushing’s syndrome.
Administration of 1 mg of DEX at 2300 h to normal subjects
suppresses the nocturnal surge in ACTH production and, as
a consequence, cortisol levels are low when measured the
next morning (11). In patients suffering from endogenous
Cushing’s syndrome of any etiology, cortisol levels are less
sensitive to DEX. Another application for this test was found
in depressed patients, who may show an insufficient cortisol
suppression in reaction to the 1-mg DST as well (12). To
interpret this test in geriatric patients, many studies were
done to investigate the effect of age per se on the duration
and pattern of cortisol suppression by DEX. Also, many
drugs and medical conditions may affect the outcome of the
DST (13). In some studies (14, 15) there were significant
correlations between age and post-DEX cortisol concentra-
tions, whereas in other studies no such correlations could be
demonstrated (16, 17). Irrespective of psychiatric distur-
bances, a decreased sensitivity to GC feedback may be prev-
alent in the very elderly (.80 yr) (18).
In the present study we investigated whether the auto-
regulatory negative feedback action of GCs on the HPA axis
changes with age. We performed a 1-mg DST in 216 healthy
elderly individuals, and 2.5 yr later a 0.25-mg DST was car-
ried out in 164 out of these 216 subjects. In addition, it was
investigated whether there was an effect of age or gender on
basal and post-DEX cortisol, as well as on the metabolism of
DEX. Furthermore it was examined whether there were dif-
ferences in response to the two doses of DEX administered,
and whether the suppression of cortisol was related to base-
line cortisol levels. Finally, the two baseline cortisol concen-
trations in the 164 individuals who underwent two exami-
nations were compared to get an impression about the
intraperson stability of these concentrations.
Subjects, Methods, and Materials
For the present study, a sample of participants from the Rotterdam
Study was invited for an additional examination. The Rotterdam study
is a population-based cohort study of the determinants of chronic dis-
abling diseases in the elderly. All approximately 10,000 inhabitants of a
suburb of Rotterdam, age 55 yr and over were invited to participate as
described elsewhere (19). The population for the present study included
216 individuals age 55–80 yr (102 men and 114 women with mean ages
of 67.7 6 5.6 and 65.8 6 6.1 yr, respectively) who had completed the
baseline visit for the Rotterdam Study not more than 6 months earlier.
Subjects with acute, psychiatric, or endocrine diseases, including dia-
betes mellitus treated with medication, were not invited. Three of the
patients used antiepileptic drugs, whereas one, who showed the lowest
pre-DEX cortisol concentration, was treated with GCs. None of them was
treated with estrogens. Compared with the other participants of the
Rotterdam Study of the same age without diabetes mellitus, there were
no differences in age and gender distribution. Written informed consent
was obtained from all subjects, and the study was approved by the
medical ethics committee of the Erasmus University Medical School.
1-mg DST
Participants were seen at the research center after an overnight fast.
Between 0800 and 0900 h blood was drawn by venapuncture to deter-
mine the serum cortisol concentrations (pre-DEX concentrations), using
RIA kits obtained from DPC (Los Angeles, CA). Intra- and interassay
variations were below 8.0% and 9.5%, respectively. Also, serum con-
centrations of the liver enzymes alanine aminotransferase (ALAT), as-
partate aminotransferase (ASAT), and g-glutamyltransferase (g-GT)
were determined, using standard methods. At the same time, the body
weight and height of the volunteers were measured, and the body mass
index (BMI, kg/m2) was calculated to be 26.4 6 0.29 for the men and
26.4 6 0.39 for the women (mean 6 se).
In the evening following the first visit to the research center, a 1-mg
DST was carried out. Participants were given a tablet of 1 mg DEX and
instructed to ingest it at 2300 h. The next morning, fasting blood samples
were obtained by venapuncture at the same time as the previous morn-
ing. In these samples, cortisol and DEX concentrations were measured.
DEX levels were estimated by RIA using an antiserum supplied by IgG
Corp. (Nashville, TN) and [3H]-DEX from Amersham (Little Chalfont,
UK). Intra- and interassay variations were below 8.5 and 14.2%, respec-
tively. Sensitivity of this assay, defined as mean result of assay of non-
DEX containing plasma 1 3 sd, was 0.13 nmol/L.
0.25-mg DST
To get more insight into individual variability of feedback sensitivity
to GCs, all 216 participants were invited for a second DST 2.5 yr later.
Out of this original group, 11 subjects had died and 6 subjects could not
be reached. Eventually, 164 individuals (76 men and 88 women with
mean ages of 69.1 6 5.9 and 67.6 6 5.6 yr, respectively), agreed to
participate in a second test. The same procedures were used as described
for the 1-mg DST but using 0.25 mg DEX. The samples obtained from
the first and the second baseline visit as well as the pre- and post-1- and
0.25-mg DEX samples were determined in separate assays. To investi-
gate possible differences in cortisol concentrations caused by interassay
variation, baseline samples obtained at the first and second examination
from 20 randomly selected subjects were determined in a single cortisol
assay.
0.25-, 0.50-, and 1-mg DST in healthy laboratory personnel
A group of nine healthy laboratory workers (age 26–49 yr) agreed to
participate in a series of DSTs with increasing doses of DEX. At intervals
of 2 weeks (to ensure the absence of interference with DEX effects from
the previous test) we performed three DSTs, using 0.25, 0.50, and 1 mg
DEX as described above. None of these individuals were using medi-
cation or oral contraceptives.
Statistical analysis
All results are reported as the mean 6 se. Serum cortisol concentra-
tions in men and women were compared using the two-sample Wil-
coxon rank-sum test. The Wilcoxon matched pairs signed rank sum test
was used to compare serum cortisol concentrations before and after DEX
administration and between the two examinations in each person.
To assess the relationships between cortisol and age and between
DEX and liver enzymes, BMI, and age, linear regression analysis was
used. To calculate the degree of association between these parameters,
the Pearson correlation coefficient (r) was calculated. Partial correlation
coefficients were used to adjust for several parameters.
Spearman’s rank correlation coefficient (r) was used to assess the
association between the DEX concentrations after the administration of
the two different doses and between basal cortisol concentrations at the
two examinations.
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Results
Baseline hormone determinations
Table 1 shows the baseline concentrations of serum cortisol
in the whole group of 216 elderly subjects and in males and
females separately. There was no difference in cortisol concen-
trations between men and women. Using linear regression anal-
ysis, no significant correlation could be demonstrated between
the baseline serum cortisol concentration and age (P . 0.2).
1-mg DST
Figure 1A shows the distribution of cortisol concentrations
before and after 1 mg DEX. Out of the 216 healthy individ-
uals, 196 (90.7%) showed a post-DEX cortisol concentration
below 50 nmol/L. Only five individuals (2.3%) had post-DEX
cortisol concentrations above 140 nmol/L, which is the cut-
off point for a normal test result when the DST is used as a
screening procedure for Cushing’s syndrome in our clinic
(20). These five individuals have been further investigated
for cortisol resistance and are reported separately (21).
As shown in Table 1, there was no difference between men
and women with regard to their post-DEX cortisol concen-
trations. There was no correlation between post-DEX cortisol
concentrations and age (P 5 0.3).
Figure 2A shows the distribution of the early morning
plasma DEX concentrations after the administration of 1 mg
DEX. None of the individuals investigated had an unmea-
surably low circulating DEX level, indicating that all partic-
ipants indeed had ingested the DEX tablets. Six individuals
had DEX concentrations below 1.8 nmol/L. Three of them
were using antiepileptic drugs.
Table 2 shows the results of the linear regression analysis
for the relationship between DEX and several factors that
might influence the metabolism of DEX. In males, there was
a positive correlation between concentrations of DEX and the
liver enzymes ALAT, ASAT, and g-GT. After deletion of the
results of the 35 men who had supranormal levels of at least
one of the enzymes, the relationship was no longer signifi-
cant. In females, these correlations were not significant, de-
spite the fact that in 21 of them increased levels of at least one
of the enzymes was found. In women there was a significant
correlation between DEX concentrations and BMI that was
not present in men. Neither in men nor in women was there
a relation between the DEX concentration and age. Baseline
cortisol concentrations were not correlated with liver func-
tion tests in either sex.
There was no significant relation between cortisol concen-
trations before and after 1 mg DEX (P . 0.1). The post-DEX
cortisol concentration and the DEX concentration itself dem-
onstrated a low but significant negative relationship (r 5
20.17, P , 0.01). This was because of the six individuals with
the lowest DEX concentrations (,1.8 nmol/L); when these
individuals were excluded from the analysis, the association
was no longer significant. Also, there was no significant
relationship between the decrease in cortisol concentrations
in reaction to DEX administration (D cortisol) and the DEX
concentration (P . 0.4).
0.25-, 0.50-, and 1-mg DST in healthy laboratory personnel
From the results of the 1-mg DST, it became clear that more
than 90% of the subjects investigated demonstrated a sup-
pression of cortisol to levels below 50 nmol/L. Therefore 1
mg DEX might be too high a suppressive dose to allow the
detection of individual differences in sensitivity of the HPA
axis to GCs. A pilot study with several doses of DEX was
subsequently carried out in nine healthy volunteers. Figure
FIG. 1. Cortisol concentrations before and after DEX administration.
A, Relative distribution of cortisol concentrations before (open bars)
and after (solid bars) 1 mg DEX in 216 healthy elderly individuals. B,
Relative distribution of cortisol concentrations before (open bars) and
after (solid bars) 0.25 mg DEX in 164 healthy elderly individuals.
Blood samples were drawn between 0800–0900 h after 1 or 0.25 mg
DEX was administered at 2300 h on the previous night. Period be-
tween two doses was approximately 2.5 yr.
TABLE 1. Cortisol concentrations (nmol/L) before and after
administration of 1 mg DEX in 216 elderly individuals
(114 females and 102 males)
Total Females Males Pa
Before DEX 521.7 6 10.4 524.8 6 14.5 517.4 6 15.4 0.89
After DEX 35.5 6 4.40 32.0 6 4.70 38.9 6 8.1 0.55
Values are mean 6 SE.
a Test for difference between males and females.
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3A shows the cortisol and DEX levels after the administration
of 0.25, 0.50, and 1 mg DEX. There was a considerable vari-
ability in baseline serum cortisol concentrations. The admin-
istration of increasing doses of DEX resulted in a dose-de-
pendent increase in mean circulating DEX levels and a dose-
dependent decrease of cortisol levels. The administration of
0.25 mg DEX even enlarged the range of serum cortisol levels:
in one subject the serum cortisol level was suppressed to a
level below 50 nmol/L, whereas in three individuals post-
DEX cortisol levels remained above 200 nmol/L. After 0.50
mg DEX, the range became more narrow, and after the ad-
ministration of 1 mg DEX, all individuals had a cortisol
concentration below 50 nmol/L.
As shown in Fig. 3B, there was a considerable individual
variability in cortisol suppression in reaction to a given DEX
concentration. This variability was not caused by individual
differences in CBG concentrations (data not shown). Using
linear regression analysis, there was no significant relation-
ship between the individual DEX concentrations and the
individual degree of cortisol suppression or the actual post-
DEX cortisol levels (all P values . 0.8). This suggests that
different individuals suppress the HPA axis to a variable
degree in reaction to similar circulating DEX concentrations.
0.25-mg DST
Anticipating that a lower dose of DEX would indeed allow
a better insight into the individual variability of the feedback
sensitivity of the HPA axis, all subjects who originally par-
ticipated in the 1-mg DST were invited to join in a 0.25-mg
DST approximately 2.5 yr later.
Table 3 shows the mean baseline levels of serum cortisol
FIG. 3. Effects of various doses of DEX on cortisol suppression. A,
Cortisol (open bars) and DEX (solid bars) concentrations after ad-
ministration of 0.25, 0.50, and 1 mg DEX in nine healthy individuals.
Blood samples were drawn between 0800–0900 h. DEX (0.25, 0.50, or
1 mg) were administered at 2300 h on the previous night at intervals
of 2 weeks. Data are means and SD of concentrations in nine indi-
viduals. B, Individual relations between logarithm of cortisol concen-
tration and DEX concentration.
FIG. 2. DEX concentrations after 1 or 0.25 mg DEX. A, Distribution
of DEX concentrations after 1 mg (n 5 216, solid bars) or 0.25 mg (n 5
164, open bars) DEX. B, Relationship between between DEX concen-
trations after 1 mg and 0.25 mg DEX; r 5 0.66, P , 0.001 in 164
subjects in whom both doses were tested. Blood samples were drawn
between 0800–0900 h after 1 or 0.25 mg DEX were administered at
2300 h on the previous night. Period between two doses was approx-
imately 2.5 yr.
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in 164 elderly subjects. The second baseline mean serum
cortisol concentrations turned out to be significantly higher
than those before the 1-mg DST. The original cortisol levels
of these 164 subjects amounted to 503.0 6 11.3 nmol/L,
whereas the follow up baseline cortisol levels were 547.8 6
1.9 nmol/L (P , 0.001). Furthermore, in these 164 individ-
uals, there was a significant difference in cortisol levels be-
tween men and women (P , 0.04). Linear regression analysis
for baseline cortisol levels and age showed no significant
correlation (P . 0.06). Random samples from 20 individuals
from both groups of baseline samples were determined in a
single assay. Mean cortisol concentrations in both groups
were identical, and there was no difference between the sexes
(data not shown). This suggests that there was no age-related
change in cortisol concentrations, but that the differences
found should be explained by the interassay variation.
Figure 1B shows the distribution of cortisol concentrations
before and after 0.25 mg DEX. There was a much wider range
in post-DEX cortisol concentrations than observed after 1 mg
DEX (cf. Fig. 1A). A small number of individuals suppressed
their cortisol levels to below a level of 140 nmol/L (n 5 34,
20.7%), whereas only nine individuals (5.5%) suppressed to
levels below 50 nmol/L.
Table 3 shows the serum cortisol concentrations after the
administration of 0.25 mg DEX. There are no differences
between men and women.
The distribution of DEX concentrations after 0.25 mg DEX
is shown in Fig. 2A. Mean DEX concentrations after this low
dose of DEX were significantly lower than after 1 mg DEX
(P , 0.001). On the other hand, as shown in Fig. 2B, subjects
who showed the highest DEX concentrations after the ad-
ministration of 1 mg DEX, also showed the highest levels
after the administration of 0.25 mg DEX (r 5 0.66, P , 0.001).
Figure 2B shows only two out of the six individuals with DEX
concentrations below 1.8 nmol/L, because four of those
showing the lowest DEX concentrations after 1 mg DEX did
not participate in the 0.25-mg DST.
Figure 4, A and B show the linear regression analysis for
the relationship between pre- and post-0.25-mg DEX cortisol
concentrations (r 5 0.39, P , 0.001), and the DEX concen-
tration and the post-DEX cortisol concentrations (r 5 20.24,
P , 0.002). Adjusting the relationship between pre- and
post-DEX cortisol concentrations for the DEX concentration
gives rise to a partial correlation coefficient of 0.43, P , 0.001.
This indicates that those individuals with the highest base-
line cortisol levels have also higher post-0.25-mg DEX cor-
tisol levels in response to a given DEX concentration.
Figure 4C shows the linear regression analysis for the DEX
concentration and D cortisol (decrease in cortisol concentra-
tion after 0.25 mg DEX), (b 5 30.7, r 5 0.31, P , 0.001).
Although there was no correlation between d cortisol and the
DEX concentration in the pilot study (n 5 9), there was an
association between these parameters in this much larger
group of individuals. The finding of a regression coefficient
of 30.7 confirms that the biological activity of DEX is about
30 times higher than the biological activity of cortisol. Figure
4C also shows that in four subjects, there was a low d cortisol
(,230 nmol/L) at DEX levels above 7 nmol/L. All four
subjects showed post-1-mg DEX cortisol concentrations be-
low 50 nmol/L. This indicates again that the 0.25-mg DST
indeed gives a better insight into individual sensitivity to
GCs than the 1-mg DST.
Individual stability of serum cortisol and CBG
concentrations
To investigate whether plasma cortisol concentrations
were stable within each person after an interval of 2.5 yr,
Spearman’s rank correlation coefficient (r) was calculated for
the baseline cortisol concentrations that were obtained at the
two examinations. Table 4 shows that there are highly sig-
nificant correlations between the concentrations determined
at an interval of 2.5 yr in both sexes. It can be concluded that
subjects with high cortisol levels at the first examination also
had a high level 2.5 yr later. The small size of the coefficient
is probably because of the interassay variation. The coeffi-
cient within the 20 samples measured in one assay was much
larger (r 5 0.59). Therefore there is indeed an intraperson
stability in the baseline early morning concentrations of these
parameters.
Discussion
Individual feedback sensitivity of the HPA axis
1 mg DST
In man, the major circulating GC hormone is cortisol.
Cortisol production in an unstressed individual follows a
nycthemeral rhythm, with peak cortisol concentrations
shortly before waking and a decline through the day, reach-
ing a nadir at bedtime. Large individual variations both in
baseline and stimulated cortisol levels have been reported
TABLE 2. Relations between DEX concentrations and liver enzymes, BMI, and age
Total Females Males
r P r P r P
ALAT (U/L) 0.19 ,0.01 0.08 0.38 0.28 ,0.01
ASAT (U/L) 0.22 ,0.01 0.14 0.13 0.25 ,0.02
gGT (U/L) 0.06 0.36 20.1 0.33 0.24 ,0.02
BMI (kg/m2) 0.12 0.07 0.24 ,0.01 20.03 0.78
Age (yr) 0.09 0.15 0.14 0.14 0.03 0.78
TABLE 3. Cortisol concentrations (nmol/L) before and after
administration of 0.25 mg DEX in 164 elderly individuals
(88 females and 76 males)
Total Females Males Pa
Before DEX 547.8 6 10.9 568.4 6 14.2 523.6 6 17.2 ,0.04
After DEX 260.5 6 10.9 243.5 6 15.2 281.3 6 16.0 0.08
Values are mean 6 SE.
a Test for difference between males and females.
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(1). One of the goals of the present study was to gain more
insight into the interindividual variability of feedback sen-
sitivity of the HPA axis, as well as into the intraindividual
stability of circulating cortisol values. In 216 healthy elderly
individuals, a 1-mg overnight DST was carried out to inves-
tigate the variability in feedback sensitivity. Only 5 out of the
216 individuals (2.3%) showed post-DEX cortisol concentra-
tions above 140 nmol/L, which is the cut-off point for a
normal test result in our clinic when the DST is used as a
screenings procedure for Cushing’s syndrome (20). These
results are in accordance with previous studies in which
nonsuppression was reported in 4% (14), 9.1% (16), and 5%
(17) of subjects. Our data demonstrate that 1 mg DEX is too
high a dose to detect individual differences in feedback sen-
sitivity within a normal population, because near total sup-
pression of cortisol levels was observed in most individuals.
Another aspect of this study was to gain more insight into
the role of the metabolism of DEX in its suppressive effects
on the HPA axis. Synthetic steroid hormones are metabolized
in the liver before being eliminated from the organism (22).
It is well known that a number of drugs influence the out-
come of a DST by altering the metabolism of DEX: e.g. sodium
phenytoin induces hepatic enzyme activity, thereby increas-
ing the metabolic clearance of GCs including DEX (23). In our
study population, there were six subjects with a DEX con-
centration below 1.8 nmol/L, three of whom were indeed on
antiepileptic drugs. In the other subjects, there was a wide
variation in DEX levels (ranging from 2.0–18.4 nmol/L).
Also, obesity might influence the outcome of a DST. In a
study by Crapo et al. (24), nonsuppression of cortisol after 1
mg DEX was reported in 1.1% of lean outpatient controls and
in 13% of obese controls. Cronin et al. (25) reported that the
degree of adiposity did not differ between patients with
false-positive responses in a DST and patients with normal
responses. The data from our study shows that in males, the
capacity of the liver to metabolize DEX is related to liver
function parameters (ALAT, ASAT, and g-GT). In women,
DEX metabolism was not related to liver enzyme levels. This
sex difference may be caused by the larger proportion of men
with liver function disturbances and the larger range of BMI
values in women. Baseline and post-DEX cortisol levels were
not related to liver function parameters and/or BMI in either
sex. Still, the influence of liver function disturbances and BMI
on the metabolism of DEX might contribute to the occurrence
of false-positive or false-negative outcomes of the 1-mg DST
in the endocrine clinic in more severely affected individuals.
In studies performed by Meikle (26) and by Weiner (27), it
was found that plasma DEX concentrations of 5.6 nmol/L
and 5.1 nmol/L, respectively, at 0800 h postadministration
are required to reliably suppress HPA function. In another
study (28) in psychiatric patients, abnormal results of the
DST were closely associated with low plasma levels of DEX.
In a study comparing patients with endogenous depression
FIG. 4. Relationships between cortisol and DEX concentrations in
0.25-mg DST. A, Linear regression analysis for relationship be-
tween pre- and post-0.25-mg DEX cortisol concentrations in 164
elderly subjects; r 5 0.39, P , 0.001. B, Linear regression analysis
for relationship between DEX concentrations and post-0.25-mg
DEX cortisol concentrations in 164 elderly subjects; r 5 20.24, P ,
0.002. C, Linear regression analysis for relationship between DEX
concentrations and change in cortisol concentration in response to
administration of 0.25 mg DEX in 164 elderly subjects; r 5 0.31,
P , 0.001.
TABLE 4. Spearman’s rank correlation coefficient between
cortisol concentrations determined at an interval of 2.5 yr
Total Females Males
rs P rs P rs P
Cortisol (nmol/L) 0.45 ,0.001 0.34 ,0.001 0.53 ,0.001
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and normal controls, it was shown that serum DEX levels
were significantly lower in nonsuppressors than in suppres-
sors (29).
0.25-, 0.50-, and 1-mg DST in healthy laboratory personnel
From the data obtained from the 1-mg DST, it became clear
that this dose might suppress the HPA axis too much to allow
the detection of individual differences of its feedback regu-
lation. A pilot study with 0.25, 0.50, and 1 mg DEX in nine
healthy laboratory workers showed that these lower doses
indeed allowed a better discrimination in HPA axis feedback
sensitivity. The broadest range of cortisol concentrations was
present after the administration of 0.25 mg DEX. This sug-
gests that the 0.25-mg DST may give a good insight into the
individual feedback sensitivity of the HPA axis.
0.25-mg DST
Out of the original group of 216 subjects, 164 persons
participated in a 0.25-mg DST. The results from the 0.25-mg
DST showed a wide range of post-DEX cortisol concentra-
tions from 14–630 nmol/L. It also became clear that there
was a close relationship between pre- and post-DEX cortisol
concentrations, a relation that was absent in the 1-mg DST.
The association became even stronger when, by calculating
a partial correlation coefficient, it was adjusted for the actual
DEX concentration. These results show that subjects with the
highest baseline cortisol concentrations also have the highest
post-0.25-mg DEX cortisol concentrations for a given DEX
concentration, and indicate that the sensitivity of the feed-
back regulation of the HPA axis is related to the baseline
cortisol concentration of the individual. This means that the
set point of the HPA axis baseline levels is related to its
feedback sensitivity.
Individual stability of cortisol concentrations
In this study, we were able to measure early morning
cortisol concentrations in a large group of healthy subjects
twice, at an interval of approximately 2.5 yr. Serum cortisol
showed an individual stability, indicating that the HPA axis
is set at a stable and reproducible set point for a given
individual. As described above, it became clear from the data
of the 0.25-mg DST that subjects with the highest baseline
cortisol concentrations also had the highest post-DEX cortisol
concentrations. It seems that within an individual, there is a
set point for HPA activity, which is defined before as well as
after a low dose of DEX. A dose of 1 mg DEX has too much
suppressive effect to demonstrate this phenomenon, but a
dose of 0.25 mg DEX, which results in a subtotal suppression
of cortisol levels, leaves the influence of the individual’s set
point of the HPA axis intact. Previous studies showed that
genetic factors may play a role in the regulation of cortisol
levels. Maxwell et al. (2) reported similar unstimulated
plasma cortisol levels in a sample of female monozygotic
twins. However, this was not found in male monozygotic
twins. Meikle et al. (3) observed evidence for a moderate
genetic impact on early morning plasma cortisol levels. A
study by Kirschbaum et al. (30) investigated cortisol re-
sponses to three different stimulation procedures (a CRH
test, a physical stimulation procedure, and a psychological
stress test), with the focus on the contribution of genetic
factors. A decided influence of genetic factors was observed
for baseline cortisol levels, as well as for the response to CRH,
but heredity appeared to play a minor role in the adreno-
cortical response to physiological stress. One of the differ-
ences between this last study and the present results is that
Kirschbaum and co-workers demonstrated a significant in-
traindividual stability of baseline cortisol concentration in
females, whereas levels in males were much less stable. In
our study, however, there was a highly significant individual
stability of baseline cortisol concentrations in both sexes.
Furthermore, the post-0.25-mg DEX cortisol levels were sig-
nificantly correlated to the baseline cortisol concentrations,
both in male and in female elderly individuals.
Effect of age on pre- and post-DEX cortisol concentrations
Studies of age-related changes in basal, nonstimulated
HPA function have produced varying results (31). Most stud-
ies have demonstrated no change or nonsignificant increases
in mean baseline ACTH (6, 8, 10) and serum cortisol levels
at older ages (32, 33). The consistent lack of age and gender
differences in basal cortisol levels across these various stud-
ies strengthens the conclusion that age does not have a major
impact on basal nonstimulated cortisol concentrations (31).
In the present study, there was no relation between age or
gender and basal total cortisol concentrations, neither in the
first nor in the second examination. Furthermore, there was
no difference between these baseline cortisol concentrations,
which were determined at an interval of approximately 2.5
yr. However, it must be stated that our study population
included elderly people only, so we were not able to compare
baseline cortisol concentrations between young and old
subjects.
We found no correlation between post-DEX cortisol con-
centrations and age, after neither 1 mg nor 0.25 mg DEX
administration. Furthermore, there was no difference be-
tween males and females in their post-DEX cortisol concen-
trations using either one of doses of DEX. Two previous
studies of healthy individuals have also demonstrated no
age-related differences in cortisol suppression after 1 mg
DEX (16, 17). In two other studies (14, 15), however, a de-
creased suppression was reported in older subjects after the
1-mg DST.
The most important conclusions from our study are the
observation of an individual stability of baseline cortisol
levels, which is closely related to the feedback sensitivity of
the HPA axis in response to a low dose of DEX. These ob-
servations suggest a genetic influence on the set point of the
HPA axis.
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